NasdaqCM:CTSO

Stock Analysis Report

Executive Summary

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide.

Snowflake

Fundamentals

High growth potential with mediocre balance sheet.

Share Price & News

How has Cytosorbents's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

6.8%

CTSO

2.0%

US Medical Equipment

1.8%

US Market


1 Year Return

-58.2%

CTSO

13.3%

US Medical Equipment

7.3%

US Market

Return vs Industry: CTSO underperformed the US Medical Equipment industry which returned 13.3% over the past year.

Return vs Market: CTSO underperformed the US Market which returned 7.3% over the past year.


Shareholder returns

CTSOIndustryMarket
7 Day6.8%2.0%1.8%
30 Day-17.9%-1.8%-0.7%
90 Day-39.4%-0.5%0.06%
1 Year-58.2%-58.2%14.2%13.3%9.7%7.3%
3 Year-16.7%-16.7%70.5%65.3%46.3%36.9%
5 Year-25.6%-25.6%127.0%101.8%64.5%46.5%

Price Volatility Vs. Market

How volatile is Cytosorbents's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cytosorbents undervalued compared to its fair value and its price relative to the market?

12.71x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: CTSO ($4.54) is trading above our estimate of fair value ($3.34)

Significantly Undervalued: CTSO is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CTSO is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: CTSO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate CTSO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CTSO is overvalued based on its PB Ratio (12.7x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is Cytosorbents forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

73.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CTSO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: CTSO is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: CTSO's loss is forecast to worsen by 0% next year.

Revenue vs Market: CTSO's revenue (32.9% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: CTSO's revenue (32.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if CTSO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Cytosorbents performed over the past 5 years?

-3.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CTSO is unprofitable, and losses have increased over the past 5 years at a rate of -3.7% per year.

Accelerating Growth: Unable to compare CTSO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CTSO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: CTSO has a negative Return on Equity (-145.89%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: CTSO is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: CTSO is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Cytosorbents's financial position?


Financial Position Analysis

Short Term Liabilities: CTSO's short term assets ($22.2M) exceeds its short term liabilities ($6.9M)

Long Term Liabilities: CTSO's short term assets (22.2M) exceeds its long term liabilities (10.0M)


Debt to Equity History and Analysis

Debt Level: CTSO's debt to equity ratio (86.5%) is considered high

Reducing Debt: CTSO's debt to equity ratio has increased from 8.3% to 86.5% over the past 5 years.


Balance Sheet

Inventory Level: CTSO has a low level of unsold assets or inventory.

Debt Coverage by Assets: CTSO's debt is covered by short term assets (assets are 2.223950x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CTSO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CTSO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Cytosorbents's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate CTSO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CTSO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CTSO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CTSO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CTSO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Cytosorbents's salary, the management and board of directors tenure and is there insider trading?

6.5yrs

Average management tenure


CEO

Phillip Chan (49yo)

10.8yrs

Tenure

US$1,247,295

Compensation

Dr. Phillip P. Chan, M.D., Ph.D. has been the Chief Executive Officer of Cytosorbents Corporation since January 2009 and serves as its President. Dr. Chan serves as a Partner of NJTC Venture Fund. He co-fo ...


CEO Compensation Analysis

Compensation vs. Market: Phillip's total compensation ($USD1.25M) is above average for companies of similar size in the US market ($USD491.38K).

Compensation vs Earnings: Phillip's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

6.5yrs

Average Tenure

61yo

Average Age

Experienced Management: CTSO's management team is seasoned and experienced (6.5 years average tenure).


Board Age and Tenure

7.9yrs

Average Tenure

71yo

Average Age

Experienced Board: CTSO's board of directors are considered experienced (7.9 years average tenure).


Insider Trading

Insider Buying: CTSO insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$31,39516 Aug 19
Kathleen Bloch
EntityIndividual
Role
Chief Financial Officer
CFO & Secretary
Shares6,500
Max PriceUS$4.83
BuyUS$8,27313 Aug 19
Kathleen Bloch
EntityIndividual
Role
Chief Financial Officer
CFO & Secretary
Shares1,500
Max PriceUS$5.52
BuyUS$19,47614 May 19
Kathleen Bloch
EntityIndividual
Role
Chief Financial Officer
CFO & Secretary
Shares3,000
Max PriceUS$6.49

Ownership Breakdown


Management Team

  • Vince Capponi (61yo)

    Chief Operating Officer

    • Tenure: 14.3yrs
    • Compensation: US$1.08m
  • Kathy Bloch (64yo)

    CFO & Secretary

    • Tenure: 6.4yrs
    • Compensation: US$953.58k
  • Phillip Chan (49yo)

    CEO, President & Director

    • Tenure: 10.8yrs
    • Compensation: US$1.25m
  • Robert Bartlett (80yo)

    Co-Chairman of Cardiac Surgery Advisory Board & Consultant

    • Tenure: 2.3yrs
    • Compensation: US$97.32k
  • Christian Steiner

    Vice President of Sales & Marketing

    • Tenure: 7.3yrs
  • Chris Cramer

    Vice President of Business Development

    • Tenure: 6.5yrs
  • Eric Mortensen (60yo)

    Chief Medical Officer

    • Tenure: 2.6yrs
    • Compensation: US$780.07k

Board Members

  • Al Kraus (75yo)

    Chairman of the Board

    • Tenure: 10.8yrs
    • Compensation: US$184.83k
  • Alan Sobel (58yo)

    Director

    • Tenure: 4.9yrs
    • Compensation: US$100.18k
  • Phillip Chan (49yo)

    CEO, President & Director

    • Tenure: 10.8yrs
    • Compensation: US$1.25m
  • Edward Jones (71yo)

    Director

    • Tenure: 12.5yrs
    • Compensation: US$91.38k
  • Robert Bartlett (80yo)

    Co-Chairman of Cardiac Surgery Advisory Board & Consultant

    • Tenure: 2.3yrs
    • Compensation: US$97.32k
  • John Kellum

    Member of Critical Care Advisory Board

    • Tenure: 0yrs
  • Ronald Maier

    Chairman of the Trauma Advisory Board

    • Tenure: 0yrs
  • Mitchell Cohen

    Member of Trauma Advisory Board

    • Tenure: 0yrs
  • Raul Coimbra

    Member of Trauma Advisory Board

    • Tenure: 0yrs
  • Joseph Zwischenberger

    Chairman of Cardiac Surgery Advisory Board

    • Tenure: 5.1yrs

Company Information

Cytosorbents Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cytosorbents Corporation
  • Ticker: CTSO
  • Exchange: NasdaqCM
  • Founded: 1997
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$146.657m
  • Shares outstanding: 32.30m
  • Website: https://www.cytosorbents.com

Number of Employees


Location

  • Cytosorbents Corporation
  • 7 Deer Park Drive
  • Suite K
  • Monmouth Junction
  • New Jersey
  • 8852
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CTSONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJul 2006
HQE1DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2006

Biography

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incor ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 23:48
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.